Competition for patients with hepatitis C virus (HCV) genotype 1 infections, the most common in the U.S. is heating up. In addition to Harvoni (ledipasvir and sofosbuvir, Gilead Sciences Inc.) and Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir, Abbvie Inc.), Merck & Co. Inc. gained FDA approval of its once-daily treatment, Zepatier (elbasvir and grazoprevir), earlier this year.
A new study in Therapeutic Innovation & Regulatory Science from the Tufts Center for the Study of Drug Development (CSDD) using data from 15 pharmaceutical companies and contract research organizations establishes price tags for the cost of implementing clinical trial amendments.
The American College of Cardiology's (ACC) annual meeting wrapped up last week with some disappointing results being presented despite the top-line outcomes of the trials being previously announced.
The public biotech markets weren't alone in taking a beating in the first quarter; venture capital investments in private U.S. biopharmas tracked by BioWorld Snapshots also saw a steep decline, with companies raising about $1.6 billion, compared to $1.9 billion in the first quarter of 2015.
Last week, Pfizer Inc. was the latest drug company to sign on to the Human Vaccines Project, a nonprofit public-private partnership with the lofty goal of decoding the immune system to make vaccine development more effective.
As biotech CEOs know all to well, what pharma taketh, pharma can giveth back. And that's especially true when the product in question isn't living up to its potential.
The promise of immuno-oncology has attracted many players to the space. More than 130 biotechs and 20 pharmaceutical companies are working on immuno-oncology therapies, according to a new report from the Tufts Center for the Study of Drug Development.
As Biogen Inc., Merck & Co. Inc. and Eli Lilly and Co. race to the finish line with their Alzheimer’s disease drugs that are in phase III development, two companies – Neuro-Bio Ltd. and Ironwood Pharmaceuticals Inc. – are just lacing up their shoes.
SAN DIEGO – At the Biocom Global Life Science Partnering Conference, biotech executives and venture capitalists shared their experiences building companies with the intention of selling to a big pharma.
SAN DIEGO – The mood at the Biocom Global Life Science Partnering Conference last week was generally upbeat on the long-term future of the sector, but venture capitalists, investment bankers, serial entrepreneurs, and other speakers at the conference warned that 2016 might be rough for raising capital.
